Search PubMed⌕ Search

Biomedical subjects

R Massei

Publications and source records attributed to R Massei.

At least 37 records · Page 2Linked to original sources
PubMed1985

Baclofen prolongs the analgesic effect of fentanyl in man.

Pretreatment with baclofen prolonged the duration of fentanyl-induced analgesia from 18 to 30 min in patients undergoing neurosurgical anaesthesia (fentanyl plus nitrous oxide in oxygen). This observation is consistent with a potentiating effect of GABA on opioid analgesia.

Adult↗
PubMed1981

[Sodium nitroprusside in neurosurgery. Clinical considerations].

The authors present their experience with SNP as hypotensive drug in surgery at cerebral aneurysms. They stress the effectiveness of SNP which they use to control deep hypotensive in 22 cases. SNP induces hypotensive in few minutes, without depressing myocardial and renal functions. The authors present also some criteria at selection of patients (to be treated with SNP during surgery) and stress the importance of monitoring blood gases during SNP hypotensive, especially te pO2 arteriovenous gradient. Using SNP at the recommended doses, and hydroxycobalamin as preventive treatment, no CN- toxicity was noted. The authors think SNP is the drug of choice for inducing deep hypotension in neurosurgery.

Adult↗
PubMedDate not supplied

Serotonin precursors in chronic primary headache. A double-blind cross-over study with L-5-hydroxytryptophan vs. placebo.

Serotonin (5-HT) plays a crucial role in mediating the descending pain inhibitory systems and in the pathophysiology of migraine. Previous studies regarding the use of 5-Hydroxytryptophan (5-HTP), the active precursor of 5-HT, in the treatment of Chronic Primary Headache (CPH) have been inconclusive so far. In order to assess the efficacy of the serotonin active precursor in chronic headache prophylaxis, a double-blind cross-over study has been carried out in 31 patients with CPH, comparing L-5-HTP to placebo. Clinical syndromes included: (a) migraine (16 patients); (b) mixed headache (6 patients); (c) psychogenic headache (5 patients); (d) muscle contraction headache (4 patients). L-5-HTP was administered for two months at daily doses of 400 mg p.o. The reduction in severity and frequency of headache in patients taking the active drug and placebo was noted. Mood patterns were also taken into consideration. L-5-HTP proved to be more effective than placebo in reducing both headache frequency and severity, but the difference was not statistically significant. Favourable responses (greater than 50% average reduction in headache symptoms) were obtained in 48% of the cases after the second month of treatment. No significant difference in therapeutic response was observed as related to different clinical syndromes, except for psychogenic headache patients, who responded poorly to the active drug. Side effects, experienced in 19% of the cases, were generally mild and transient. We conclude that L-5-HTP is a medication of moderate efficacy and remarkable safety, providing us with another alternative approach to CPH prophylaxis.

5-Hydroxytryptophan↗